A Prospective, Open-Label, Multicenter Study Comparing Lymphoseek and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2017
At a glance
- Drugs Tc 99m tilmanocept (Primary)
- Indications Malignant melanoma; Rhabdomyosarcoma; Solid tumours
- Focus Diagnostic use
- Sponsors Cardinal Health; Navidea Biopharmaceuticals
- 21 Sep 2017 Planned End Date changed from 1 Sep 2017 to 1 Jun 2021.
- 21 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jun 2021.
- 27 Jun 2017 Status changed from active, no longer recruiting to recruiting.